A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion

G Agaësse1,2,3, L Barbollat-Boutrand1,2,3, E Sulpice4,5,6

  • 1Université de Lyon, Lyon, France.

Oncogene
|July 5, 2016
PubMed

Insights

Researchers identified LCMR1 as a key regulator of Tspan8 expression in melanoma, a protein crucial for early invasion. This finding reveals new therapeutic targets for deadliest skin cancer, potentially improving patient survival rates.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Melanoma is the deadliest skin cancer, characterized by high metastasis rates and frequent relapse after treatment.
  • Tetraspanin 8 (Tspan8) expression increases with melanoma progression and enhances cell invasiveness.
  • Understanding molecular mechanisms of early melanoma invasion is critical for improving patient survival.

Purpose of the Study:

  • To identify transcriptional regulators of Tspan8 expression in melanoma.
  • To investigate the role of Liver Carcinoma Metastasis Suppressor 1 (LCMR1) in melanoma progression.
  • To explore potential therapeutic targets for melanoma invasion.

Main Methods:

  • Performed an RNA interference-based screen to identify Tspan8 transcriptional regulators.
  • Investigated the functional role of LCMR1 in melanoma cell lines.
  • Analyzed the correlation between LCMR1 and Tspan8 expression in melanoma lesions.
  • Assessed the effect of vemurafenib on LCMR1 and Tspan8 expression.

Main Results:

  • Identified several Tspan8 regulators, including GSK3β, PTEN, IQGAP1, TPT1, and LCMR1.
  • LCMR1 was identified as the first direct target regulating Tspan8 expression.
  • LCMR1 overexpression led to increased melanoma cell invasion and tumorogenicity in vivo.
  • LCMR1 and Tspan8 overexpression correlated in melanoma lesions and were downregulated by vemurafenib.

Conclusions:

  • Tspan8 and its regulators, particularly LCMR1, are crucial in controlling early melanoma invasion.
  • LCMR1-Tspan8 axis represents a promising therapeutic target for melanoma.
  • These targets are downstream of the RAF-MEK-ERK signaling pathway, offering potential for targeted therapy.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K